By Chris Wack

 

F-star Therapeutics Ltd. shares were up 9% to $6.96 in premarket trading Wednesday after the biopharmaceutical company said it entered into a license and collaboration agreement with Johnson & Johnson's Janssen Biotech Inc.

Under the terms of the agreement, F-star said it will grant Janssen a worldwide, exclusive royalty-bearing license to research, develop, and commercialize up to five novel bispecific antibodies directed to Janssen therapeutic targets using F-star's proprietary Fcab and mAb platforms.

Janssen will be responsible for all research, development, and commercialization activities under the agreement.

F-star said it is entitled to receive upfront fees of $17.5 million, and near-term fees and potential further milestones of up to $1.35 billion. F-star is also eligible to receive potential tiered mid-single digit royalties on annual net sales.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

October 20, 2021 08:43 ET (12:43 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Nov 2021 to Dec 2021 Click Here for more Johnson and Johnson Charts.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Dec 2020 to Dec 2021 Click Here for more Johnson and Johnson Charts.